Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib in advanced solid tumors
NCT03976050Phase 1Terminated
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Jun 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tunlametinib in solid tumor (advanced stage), sponsored by Shanghai KeChow Pharmaceuticals. Primary endpoints: Adverse events at 24 months, Dose limitation toxicities at 28 days and 1 more. Started Jun 2019; status: terminated.
02
Drugs
tunlametinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03976050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976050.